Saturday, October 13, 2007

Cigarette Smoking May Accelerate Disability In Those With MS
Science Daily (press release) - USA
... nine had primary-progressive MS -- steady worsening from onset; and 90 had secondary-progressive MS, characterized by occasional attacks and sustained ...
See all stories on this topic

Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions In Patients Receiving Interferon Beta ...
Medical News Today Fri, 12 Oct 2007 1:17 AM PDT
Biogen Idec Inc. (Nasdaq: BIIB) and PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced that Phase 2 data demonstrated a significant reduction in new or enlarged gadolinium-enhancing lesions when daclizumab is added to interferon beta therapy in patients with active relapsing multiple sclerosis (MS). [click link for full article]

Familial MS May Be More Destructive
HealthDay via Yahoo! News Fri, 12 Oct 2007 6:00 AM PDT
FRIDAY, Oct. 12 (HealthDay News) -- Multiple sclerosis that runs in families appears to cause more severe brain damage than the non-familial form, say University at Buffalo researchers.

MS That Runs in Families May Be Worse
WebMD Fri, 12 Oct 2007 11:45 AM PDT
Multiple sclerosis may cause more severe brain damage in patients who have a relative who had multiple sclerosis, a study shows.

Familial MS May Be More Destructive
KOLD News 13 Tuscon Fri, 12 Oct 2007 7:27 AM PDT
FRIDAY, Oct. 12 (HealthDay News) -- Multiple sclerosis that runs in families appears to cause more severe brain damage than the non-familial form, say University at Buffalo...

New TYSABRI(R) Data to Be Presented at the European Committee for ...
NDTV.com - New Delhi,India
The proportion of disease-free patients over two years was significantly higher in the TYSABRI-treated group compared with the placebo group regardless of ...
See all stories on this topic

Biogen Idec Says Icahn Expressed Interest in Buying (Update4)
Bloomberg - USA
Regulators allowed Biogen and its partner Elan Corp. to resume selling the drug, Tysabri, last year because of its effectiveness. Biogen last month forecast ...
See all stories on this topic

Teva reports positive data for MS drug
CNNMoney.com - USA
Copaxone has faced growing competition from Tysabri, made by Biogen Idec Inc. (NASDAQ:BIIB) and Elan Corp. That drug was approved in 2004, but pulled from ...
See all stories on this topic

Biogen Idec Exploring Potential Sale
The Associated Press -
The results boosted the stock to its highest level since the company withdrew a newer MS drug called Tysabri in February 2005 because of safety concerns. ...
See all stories on this topic

Biogen Idec Puts Itself On The Block
RTT News - Williamsville,NY,USA
The company, which makes multiple sclerosis drugs Avonex, Tysabri and non-Hodgkin's lymphoma drug Rituxan, employs about 3900 people worldwide. ...
See all stories on this topic

Biogen Idec may consider selling company
BusinessWeek - USA
The company, which makes Rituxan, Tysabri and Avonex, said it has received expressions of interest, including one from investor Carl Icahn. ...
See all stories on this topic

New Preclinical Data Suggests FTY720 May Repair or Reduce Damage ...
PharmaLive.com (press release) - Newtown,PA,USA
This mechanism of action may be in addition to the established anti-inflammatory role of FTY720 that is mediated by the reduction of inflammatory immune ...
See all stories on this topic

To travel hopefully
St. John's Telegram - St. John's,Newfoundland and Labrador,Canada
I've been asked to speak at the 15th Interurban Conference on Spinal Cord Injury, sponsored by McMaster University in Hamilton. No problem. ...
See all stories on this topic

NeoStem Announces Opening Of Las Vegas Adult Stem Cell
BioResearch Online (press release) - Horsham,PA,USA
New York - NeoStem, Inc., a biotechnology services company capitalizing on breakthroughs in the burgeoning field of adult stem cell therapeutics, ...
See all stories on this topic

Biogen Idec and Elan's data supports use of Tysabri
Trading Markets (press release) - Los Angeles,CA,USA
The proportion of disease-free patients in the Affirm (Antegren safety and efficacy in relapsing-remitting multiple sclerosis) study was determined based ...
See all stories on this topic

MS That Runs In Families Appears More Severe Than Non-familial MS
Science Daily (press release) - USA
Of these patients, 478 had relapsing-remitting MS, involving acute attacks with full or partial recovery; 222 had secondary-progressive MS, characterized by ...
See all stories on this topic

ECTRMS: Family History Worsens MS Severity
MedPage Today - Little Falls,NJ,USA
Among them, 478 had relapsing-remitting MS, 222 had secondary-progressive disease, 30 had primary-progressive MS, and 29 had experienced their first ...
See all stories on this topic

0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home